Singapore, April 30, 2008: Research organizations around the world announced that they are launching the International Cancer Genome Consortium (ICGC), a collaboration designed to generate high-quality genomic data on up to 50 types of cancer through efforts projected to require up to a decade. The ICGC, which is extending an invitation to all nations to participate, will make its data rapidly and freely available to the global research community.

 

Singapore is one of the country members in the consortium, represented by the Genome Institute of Singapore (GIS), a part of Singapore’s Agency for Science, Technology and Research (A*STAR). Dr Edison Liu, Executive Director, GIS, said, “What we will be doing is to develop a complete genetic map of human cancers. Singapore has been asked to be a leader in this international effort, which is an indication of our progress in this field.”

 

“Cancer’s complexity poses an enormous challenge. National Institutes of Health (NIH) is highly encouraged that the worldwide scientific community is joining together to meet this challenge, and we are pleased to be a member of this ambitious international endeavor. The Consortium’s commitment to making its data rapidly available in public databases will serve to accelerate research into the causes and control of cancer in the United States and throughout the world,” said Director Dr Elias A. Zerhouni, director, NIH.

 

Each ICGC member intends to conduct a comprehensive, high-resolution analysis of the full range of genomic changes in at least one specific type or subtype of cancer, with studies built around common standards of data collection and analysis. Each project is expected to involve specimens from approximately 500 patients and have an estimated cost of $20 million.

 

As part of its coordination efforts, the ICGC will generate a list of approximately 50 cancer types and subtypes that are of clinical significance around the globe. ICGC members plan to assume responsibility for specific cancers, and one of the ICGC’s roles will be to facilitate the exchange of information so participants’ efforts do not duplicate each other.

 

Current ICGC members include: Australia: National Health and Medical Research Council (Observer Status), Canada: Genome Canada (Observer Status); Ontario Institute for Cancer Research, China: Chinese Cancer Genome Consortium, Europe: European Commission (Observer Status), France: Institut National du Cancer, India: Department of Biotechnology, Ministry of Science & Technology, Japan: RIKEN; National Cancer Center, Singapore: Genome Institute of Singapore, United Kingdom: The Wellcome Trust; Wellcome Trust Sanger Institute, United States: National Institutes of Health.  

 

“Clearly, there is an urgent need to reduce cancer’s terrible toll. To help meet that need, the Consortium will use new genome analysis technologies to produce comprehensive catalogs of the genetic mutations involved in the world’s major types of cancer. Such catalogs will be valuable resources for all researchers working to develop new and better ways of diagnosing, treating and preventing cancer,” said Dr Thomas Hudson, of the ICGC Secretariat, which is based at the Ontario Institute for Cancer Research in Toronto.

 

The ICGC’s main criteria for prioritizing cancer types will be: impact, including incidence and mortality rates, availability of therapies and age of onset; scientific interest; and feasibility, which includes the ability to obtain enough high-quality samples to conduct a large-scale project.

 

To facilitate comparisons among different types of cancer, the ICGC guidelines list key factors for its members to consider in the production of genomic catalogs. Those factors include comprehensiveness, which involves detecting all cancer genes mutated in at least 3 per cent of tumor samples; resolution, which involves generating data at the level of individual DNA bases; quality, which involves monitoring based on common standards for pathology and technology; and controls, which involves comparisons of data from matched, non-tumor tissue.

 

ICGC member nations plan to agree to common standards for informed consent and ethical oversight. While the informed consent process will necessarily differ according to each member country’s requirements, the consortium’s policies state that cancer patients enrolled in an ICGC-related study should be informed that their participation is voluntary, that their clinical care will not be affected by their participation and that data obtained from analyses using their samples will be made available to the international research community. ICGC members will ensure that all samples will be coded and stored in ways that protect the identities of the participants in the study.

           

To maximize the public benefit from ICGC member research, data will be made rapidly available to qualified investigators. In addition, all consortium participants will agree not to file any patent applications or make other intellectual property claims on primary data from ICGC projects.

 

Worldwide, more than 7.5 million people died of cancer and more than 12 million new cases of cancer were diagnosed in 2007. Unless progress is made in understanding and controlling cancer, those numbers are expected to rise to 17.5 million deaths and 27 million new cases in 2050.